Clinical Trial Update: Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age [Phase 1]

View source ↗

Summary

Phase 1 clinical trial assessing safety and immunogenicity of pneumococcal conjugate formulations in healthy adults aged 18-49; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Pfizer pneumococcal conjugate formulations

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Phase 1 | Status: COMPLETED | Results posted: 2024-04-18